From survival to survivorship: late side effects become an issue in high-grade glioma

References

• DeAngelis LM. Brain tumors. N. Eng. J. Med.344, 114–123 (2001).
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol.64, 479–489 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Eng. J. Med.352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.10, 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl Cancer Inst.85, 704–710 (1993).
   PubMed Web of Science ®Google Scholar
• Krex D, Klink B, Hartmann C et al. Long-term survival with glioblastoma multiforme. Brain130, 2596–2606 (2007).
   PubMed Web of Science ®Google Scholar
• Weller M, Felsberg J, Hartmann C et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin.Oncol.27, 5743–5750 (2009).
   PubMed Web of Science ®Google Scholar
• Liu Y, Shete S, Etzel CJ et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J. Clin. Oncol.28, 2467–2474 (2010).
   PubMed Web of Science ®Google Scholar
• Felsberg J, Rapp M, Loeser S et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin. Cancer Res.15, 6683–6693 (2009).
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res.16, 2443–2449 (2010).
   PubMed Web of Science ®Google Scholar
• al-Mefty O, Kersh JE, Routh A, Smith RR. The long-term side effects of radiation therapy for benign brain tumors in adults. J. Neurosurg.73, 502–512 (1990).
   PubMed Web of Science ®Google Scholar
• Armstrong CL, Gyato K, Awadalla AW, Lustig R, Tochner ZA. A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy. Neuropsychol. Rev.14, 65–86 (2004).
   PubMed Web of Science ®Google Scholar
• Balducci M, Mattiucci GC, Dinapoli N et al. Impact of dose and volume on the tolerance of central nervous system. Rays30, 189–195 (2005).
   PubMedGoogle Scholar
• Chong VF, Khoo JB, Chan LL, Rumpel H. Neurological changes following radiation therapy for head and neck tumours. Eur. J. Radiol.44, 120–129 (2002).
   PubMed Web of Science ®Google Scholar
• Lawrence YR, Li XA, el Naqa I et al. Radiation dose-volume effects in the brain. Int. J. Radiat. Oncol. Biol. Phys.76, S20–S27 (2010).
   PubMed Web of Science ®Google Scholar
• Armstrong C, Ruffer J, Corn B, DeVries K, Mollman J. Biphasic patterns of memory deficits following moderate-dose partial-brain irradiation: neuropsychologic outcome and proposed mechanisms. J. Clin. Oncol.13, 2263–2271 (2995).
   Google Scholar
• Movsas B. Phase III study of prophylactic cranial irradiation (PCI) versus observation in patients with stage III non-small cell lung cancer (NSCLC): neurocognitive and quality of life (QOL) analysis of RTOG 0214. In: Annual Meeting of American Society for Radiation Oncology, Chicago, IL, USA, 1–5 November 2009.
   Google Scholar
• Douw L, Klein M, Fagel SS et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol.8, 810–818 (2009).
   PubMed Web of Science ®Google Scholar
• Brown RT, Madan-Swain A, Walco GA et al. Cognitive and academic late effects among children previously treated for acute lymphocytic leukemia receiving chemotherapy as CNS prophylaxis. J. Pediatr. Psychol.23, 333–340 (1998).
   PubMed Web of Science ®Google Scholar
• Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist10, 293–310 (2004).
   PubMed Web of Science ®Google Scholar
• Ellenberg L, McComb JG, Siegel SE, Stowe S. Factors affecting intellectual outcome in pediatric brain tumor patients. Neurosurgery21, 638–644 (1987).
   PubMed Web of Science ®Google Scholar
• Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology62, 548–555 (2004).
   PubMed Web of Science ®Google Scholar
• Harder H, Holtel H, Bromberg JE et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology62, 544–547 (2004).
   PubMed Web of Science ®Google Scholar
• Schlegel U, Pels H, Oehring R, Blumcke I. Neurologic sequelae of treatment of primary CNS lymphomas. J. Neurooncol.43, 277–286 (1999).
   PubMedGoogle Scholar
• Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J. Clin. Oncol.25, 2455–2463 (2007).
   PubMed Web of Science ®Google Scholar
• Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin. Neuropsychol.20, 76–89 (2006).
   PubMed Web of Science ®Google Scholar
• Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann. Oncol.19, 623–629 (2008).
   PubMed Web of Science ®Google Scholar
• Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol.18, 1481–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Chaichana KL, Halthore AN, Parker SL et al. Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. J. Neurosurg. DOI:10.3171/2010.4.JNS091340 (2010) (Epub ahead of print).
   Google Scholar
• Taphoorn MJ, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol.6, 937–944 (2005).
   PubMed Web of Science ®Google Scholar
• Hottinger AF, Yoon H, DeAngelis LM, Abrey LE. Neurological outcome of long-term glioblastoma survivors. J. Neurooncol.95, 301–305 (2009).
   PubMedGoogle Scholar
• Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer116(17), 3988–3999 (2010).
   PubMed Web of Science ®Google Scholar
• Lawrence YR, Wang M, Dicker A et al. Acute neurological toxicity (NT) and long-term outcomes in high-grade glioma RTOG trials. J. Clin. Oncol.28(Suppl. 1), abstract 2037 (2010).
   Google Scholar
• Baschnagel A, Wolters P, Camphausen K. Neuropsychological testing and biomarkers in the management of brain metastases. Radiat. Oncol.3, 26 (2008).
   PubMedGoogle Scholar
• Falleti MG, Maruff P, Collie A, Darby DG. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test–retest intervals. J. Clin. Exp. Neuropsychol.28, 1095–1112 (2006).
   PubMed Web of Science ®Google Scholar